Society for Cardiovascular Angiography Interventions (SCAI)

The Society for Cardiovascular Angiography and Interventions (SCAI) represents interventional cardiology through education, advocacy, research, setting guidelines and quality patient care. SCAI provides thought leadership in cath lab procedures, new technology and policy.

RSS icon
Early clinical evaluation of the Alleviant System to create no-implant interatrial shunts to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) demonstrated procedural safety and feasibility with a promising efficacy signal through six months.

Key interventional cardiology takeaways from the SCAI 2022 conference

The key interventional cardiology takeaways from sessions presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2022 annual meeting.

TPV valves, CTO PCI and more: SCAI 2022 updates for interventional cardiologists

The first two days of SCAI 2022 were jam-packed with innovative technologies and late-breaking research.

Thumbnail

New guidelines detail PFO management, including when to consider closure

The new guidance document was designed to provide helpful information on a topic "surrounded by controversy." 

Kirk Garratt, past SCAI president, explains the impact of the iodine contrast shortage on interventional cardiology and the cath lab. #SCAI

VIDEO: How the iodine contrast shortage is impacting interventional cath labs

Kirk Garratt, MD, medical director of the Center for Heart and Vascular Health, ChristianaCare, and a past president of SCAI, explains what this shortage means for interventional cardiologists.

Intravascular lithotripsy (IVL) Shockwave Medical PCI PAD CAD Disrupt PAD Disrupt CAD SCAI 2022

Intravascular lithotripsy tied to superior long-term PAD, PCI outcomes at SCAI 2022

Two separate sessions presented at SCAI 2022 focused on long-term outcomes associated with Shockwave Medical's IVL technology.

Cardiologists join the FDA’s fight against menthol cigarettes, flavored cigars

The American College of Cardiology (ACC), Association of Black Cardiologists, American Heart Association and Society for Cardiovascular Angiography & Interventions are just some of the healthcare organizations supporting the FDA's proposal.

Several ACC 2022 late-breaking trials may have impacts on clinical practice for interventional cardiology and structural heart. One trial compared FFR vs. IVUS guided PCI for intermediate coronary lesions. Photos by Dave Fornell

Key interventional cardiology takeaways from ACC.22

Several late-breaking clinical trials at ACC.22 will likely impact clinical practice. Below are summaries of a few key trials and their takeaways for interventional cardiology and structural heart interventions. 

A late-breaking study at ACC.22 showed differences in COVID-positive heart attack patients between 2020 and 2021. #ACC22 #ACC2022

VIDEO: Vaccines boosted survival among STEMI heart attack patients with COVID-19

Santiago Garcia, MD, lead author of the study and director of the structural heart program at The Christ Hospital in Cincinnati, Ohio, presented new data from the North American COVID-19 STEMI (NACMI) registry at ACC.22. Severity of heart attacks were reduced in vaccinated patients, with zero deaths in vaccinated patients in 2021.

Displaying 65 - 72 of 97

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup